A carregar...
Development of Antibody‐Directed Therapies: Quo Vadis?
Less is more: The efficacy of antibody–drug conjugates (ADCs) for cancer therapy is traditionally associated with cleavable linkers for payload release. Evidence now suggests that simpler constructs without cleavable moieties can afford more stable and effective ADCs.[Image: see text]
Na minha lista:
| Publicado no: | Angew Chem Int Ed Engl |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5838556/ https://ncbi.nlm.nih.gov/pubmed/29341367 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/anie.201712185 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|